Gastritis Treatment Guidelines

First-Line Treatments

The American Gastroenterological Association recommends proton pump inhibitors (PPIs) as the first-line treatment for gastritis, with high-potency options like esomeprazole or rabeprazole (20-40 mg twice daily) being most effective for symptom relief and healing 1, 2, 3
Rabeprazole is recommended at a dose of 20 mg twice daily, equivalent to 36 mg of omeprazole, for the treatment of gastritis 1, 3
Esomeprazole is recommended at a dose of 20-40 mg twice daily, equivalent to 32 mg of omeprazole, for the treatment of gastritis 1, 3
Lansoprazole is recommended at a dose of 30 mg twice daily, equivalent to 27 mg of omeprazole, for the treatment of gastritis 1, 3
Pantoprazole should be avoided when possible due to lower potency, with 40 mg pantoprazole being equivalent to 9 mg omeprazole 1, 3

Treatment for H. pylori-Associated Gastritis

The American College of Gastroenterology recommends bismuth quadruple therapy for 14 days as the preferred first-line treatment for H. pylori-associated gastritis due to increasing antibiotic resistance 4
Concomitant 4-drug therapy is an alternative first-line option when bismuth is unavailable 4
Clarithromycin triple therapy, metronidazole triple therapy, and levofloxacin triple therapy are options for H. pylori treatment, with the choice of therapy guided by local resistance patterns and previous treatment attempts 2, 4
Higher-potency PPIs, such as rabeprazole or esomeprazole, improve eradication rates of H. pylori 1, 2, 3

Adjunctive Treatments

Antacids provide rapid, temporary relief of symptoms and can be used on-demand for breakthrough symptoms 5, 6
Misoprostol, a synthetic PGE1, reduces NSAID-associated gastric ulcers by 74% and duodenal ulcers by 53%, but its use is limited by side effects such as diarrhea, abdominal pain, and nausea 6, 7

Special Considerations

The American Heart Association recommends using the lowest effective NSAID dose for the shortest duration to minimize the risk of NSAID-induced gastritis 7
PPI therapy should be added for gastroprotection in high-risk patients taking NSAIDs 7
H. pylori eradication should be considered before starting long-term NSAID therapy 6
Inadequate PPI dosing and premature discontinuation of treatment are common pitfalls to avoid in the treatment of gastritis 1, 3, 5
Failure to address H. pylori infection is a common pitfall to avoid in the treatment of gastritis 4

Treatment of H. pylori-Associated Gastritis

Diagnosis and Treatment

Testing for H. pylori should be performed using non-invasive tests such as urea breath test (UBT) or monoclonal stool antigen tests, as recommended by the European Society of Gastrointestinal Endoscopy 8
H. pylori eradication produces long-term relief of dyspepsia in approximately 1 in 12 patients with functional dyspepsia, according to the American Gastroenterological Association 8
H. pylori eradication is beneficial and should be performed before starting NSAID treatment, especially in patients with a history of peptic ulcers, as suggested by the European Helicobacter Study Group 9, 10
Eradication of H. pylori in patients receiving long-term PPIs heals gastritis and prevents progression to atrophic gastritis, as recommended by the American College of Gastroenterology 10

Special Considerations

Relying solely on symptom resolution without confirming H. pylori eradication can lead to persistent infection and complications, as warned by the World Gastroenterology Organisation 8, 10
Long-term PPI treatment in H. pylori-positive patients is associated with the development of corpus-predominant gastritis, which accelerates the progression to atrophic gastritis, according to the European Society of Gastrointestinal Endoscopy 9, 10

Management of Recurring Gastritis After H. pylori Eradication

Understanding Post-H. pylori Eradication Gastritis

Residual symptoms following successful H. pylori eradication are common, with many patients continuing to experience dyspeptic symptoms despite confirmed eradication of the infection 11, 12
The Maastricht consensus guidelines acknowledge that a significant proportion of patients with functional dyspepsia will continue to have symptoms following successful eradication of H. pylori and will require effective therapy 13
H. pylori eradication does not guarantee complete symptom resolution, as it eliminates the risk of peptic ulcer mortality but may not address all underlying gastric inflammation 11

Appropriate Management of Recurring Symptoms

For patients with residual symptoms following successful H. pylori eradication therapy (confirmed by negative tests), treatment should be individualized based on the predominant symptom 11, 13
Full-dose PPI therapy (such as pantoprazole 40 mg once daily) is the recommended first-line treatment for patients with epigastric pain or reflux symptoms after H. pylori eradication 11

Rationale for PPI Therapy

For patients with ulcer-like dyspepsia (epigastric pain) or reflux symptoms, PPI therapy confirms the acid-related nature of the symptoms 11
The Genval guidelines recommend initial first-line therapy with full-dose PPI therapy for symptomatic gastroesophageal reflux disease (GORD), which may be present after H. pylori eradication 11

Follow-up and Monitoring

Gradual improvement of symptoms with fluctuations is expected with appropriate treatment 11
The absence of alarm symptoms (bleeding, vomiting, weight loss) is reassuring and suggests a benign course 11

Common Pitfalls to Avoid

Inadequate PPI dosing (timing relative to meals) can reduce effectiveness - PPIs should be taken 30 minutes before eating 14

Treatment of Acute Gastritis

First-Line Medication Options

H2-Receptor Antagonists (H2RAs) are less effective than PPIs for healing gastric lesions but provide faster symptom relief, according to the American Academy of Pediatrics 15
H2RAs decrease the risk of duodenal ulcers but are less effective for gastric ulcers, as stated by the American Gastroenterological Association 16

Special Considerations

If H. pylori Infection is Present

The American Gastroenterological Association recommends bismuth quadruple therapy for 14 days (PPI + bismuth + metronidazole + tetracycline) for H. pylori positive patients 17

If NSAID-Induced Gastritis

The American Gastroenterological Association advises discontinuing NSAIDs if possible, and if NSAIDs must be continued, adding PPI therapy for gastroprotection 16

General Treatment

The American College of Cardiology states that PPIs have been proven superior to both H2RAs and misoprostol in preventing ulcer recurrence and overall symptom control, making them the rational first choice for treatment of acute gastritis 18

Gastritis Treatment Guidelines

Diagnosis and Treatment

All individuals with gastritis should be assessed for H. pylori infection, and if positive, eradication therapy should be administered and successful eradication confirmed using non-serological testing, as recommended by the American Gastroenterological Association 19
H. pylori eradication heals gastritis and prevents progression to atrophic gastritis in patients receiving long-term PPIs, according to the European Society of Gastrointestinal Endoscopy 20
Check antiparietal cell antibodies and anti-intrinsic factor antibodies to assist with diagnosis of autoimmune gastritis, and evaluate for anemia due to vitamin B-12 and iron deficiencies, as suggested by the American Gastroenterological Association 19
Screen for concomitant autoimmune disorders, particularly autoimmune thyroid disease, in patients with autoimmune gastritis, as recommended by the American Gastroenterological Association 19

Follow-up and Monitoring

Surveillance endoscopy every 3 years should be considered in individuals with advanced atrophic gastritis, as recommended by the American Gastroenterological Association 19
For autoimmune gastritis, interval endoscopic surveillance should be considered based on individualized risk assessment, as suggested by the American Gastroenterological Association 19
Failure to evaluate for vitamin B-12 and iron deficiencies in patients with atrophic gastritis can lead to inadequate management, as noted by the American Gastroenterological Association 19

Gastritis Pain Management with Proton Pump Inhibitors and NSAID Precautions

Gastroprotective Strategies for Unavoidable NSAID Use

The American Gastroenterological Association recommends using PPIs to reduce endoscopic NSAID-related ulcers by 90% in patients who cannot discontinue NSAIDs 21
The American Gastroenterological Association suggests that misoprostol 600-800mg daily reduces NSAID-associated GI complications by 40% and gastric ulcers by 74%, but causes diarrhea and abdominal pain in ~20% of patients, limiting tolerability 21
H2-receptor antagonists are inadequate for gastroprotection as they decrease duodenal ulcer risk but not gastric ulcer risk, according to the American Gastroenterological Association 21, 22

Risk Stratification and Monitoring

The American College of Gastroenterology recommends that high-risk patients, including those with a history of previous ulcer or ulcer complication, require intensive gastroprotection 21
The American College of Gastroenterology suggests that concomitant corticosteroid use is a risk factor for NSAID-related complications, and recommends combining a COX-2 inhibitor with a PPI for high-risk patients 22

Common Pitfalls to Avoid

The American Gastroenterological Association warns that using buffered or coated aspirin does not significantly decrease GI risk, and recommends against combining NSAIDs due to dramatically increased risk, especially with aspirin 21, 22

Management of Acute Gastritis

Immediate Treatment and Prevention of NSAID-Induced Gastritis

The American Gastroenterological Association recommends discontinuing all NSAIDs immediately if clinically feasible in patients with suspected NSAID-induced gastritis 23, 24
If NSAIDs cannot be stopped, high-dose PPI therapy should be continued indefinitely for gastroprotection, and the lowest effective NSAID dose should be used for the shortest duration 23, 24
The American College of Gastroenterology advises against combining multiple NSAIDs, as this dramatically increases GI risk 23
In high-risk patients requiring continued anti-inflammatory therapy, consider switching to a COX-2 selective inhibitor plus PPI 24

Adjunctive Therapy for Gastritis

Misoprostol reduces NSAID-associated gastric ulcers by 74% at doses of 600-800 mg daily, but is limited by significant side effects such as diarrhea, abdominal pain, and nausea in ~20% of patients 23, 24
H2-receptor antagonists are not recommended as they are significantly less effective than PPIs for gastric protection and only reduce duodenal (not gastric) ulcer risk 23, 24

Risk Stratification and Prevention

High-risk patients requiring intensive gastroprotection include those with previous peptic ulcer or ulcer complication, age >65 years, concurrent corticosteroid use 23, concurrent anticoagulation or antiplatelet therapy 23, and high-dose or multiple NSAID use 24
For these patients, combining a COX-2 inhibitor with a PPI is recommended for maximum protection 24

Special Considerations

The American Gastroenterological Association recommends that H. pylori eradication should be performed before starting long-term NSAID therapy, especially in patients with previous ulcer history 24
In patients already on NSAIDs with H. pylori infection, eradication reduces ulcer recurrence but does not eliminate NSAID-related risk 24
Both PPI therapy and H. pylori eradication are necessary in infected patients requiring continued NSAIDs—eradication alone is insufficient 24

Treatment Guidelines for H. pylori-Positive Gastritis

Diagnostic Testing and Treatment Algorithm

The World Journal of Emergency Surgery recommends testing every gastritis patient for H. pylori using urea breath test (sensitivity 88-95%, specificity 95-100%) or monoclonal stool antigen test (sensitivity 94%, specificity 92%) 25
The World Journal of Emergency Surgery suggests metronidazole 500 mg twice daily as part of the bismuth quadruple therapy for 14 days 25
The World Journal of Emergency Surgery recommends levofloxacin 500 mg once daily (or 250 mg twice daily) as part of the second-line treatment if first-line fails 25
The World Journal of Emergency Surgery suggests amoxicillin 1000 mg twice daily as part of the second-line treatment if first-line fails 25
The World Journal of Emergency Surgery recommends high-potency PPI twice daily for 10-14 days as part of the second-line treatment if first-line fails 25

Suplementación Post-Tratamiento para H. pylori

Posición de las Guías Clínicas sobre Suplementos

Las terapias adyuvantes propuestas, incluyendo probióticos, son de beneficio no comprobado para el tratamiento de la infección por H. pylori y su uso debe considerarse experimental, según la American Gastroenterological Association (AGA) 26, 27
No hay recomendaciones basadas en evidencia para suplementos específicos después de la erradicación exitosa, según la American Gastroenterological Association (AGA) 26, 27

Consideraciones Especiales

La erradicación de H. pylori cura la gastritis y previene la progresión a gastritis atrófica en pacientes que reciben IBP a largo plazo, según la sociedad de Gastroenterología 28
Después de la erradicación exitosa, el riesgo residual de sangrado por úlcera péptica debido al uso continuo de aspirina es muy bajo, según la sociedad de Gastroenterología 28
El tratamiento con IBP a largo plazo en pacientes H. pylori positivos se asocia con el desarrollo de gastritis de predominio corporal, acelerando la progresión a gastritis atrófica, según la sociedad de Gastroenterología 28